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Purpose: Inflammation plays an important role in dry eye syndrome. In this study, inflammatory cytokine expression on
the ocular surface in the Botulium toxin B (BTX-B) induced mouse dry eye model was investigated.
Methods: CBA/J mice received an injection of saline or 20 milliunits (mU) of BTX-B into the lacrimal gland. Tear
production and corneal fluorescein staining were evaluated in all groups before injection and at 3 time points after. The
pro-inflammatory cytokines macrophage inhibitory factor (MIF), interleukin-1β (IL-1 β), tumor necrosis factor-α (TNF-
α) and interleukin-6 (IL-6) in conjunctival and corneal epithelium were evaluated by real time quantitative PCR and
immunohistochemistry.
Results: BTX-B injected mice showed significantly decreased aqueous tear production and increased corneal fluorescein
staining at the 1 week and 2 week time points compared with normal control and saline-injected mice. The BTX-B injected
mice mRNA expression levels of TNF-α and IL-1β from conjunctival and corneal epithelial cells increased significantly
at two early time points comparing with that of normal and saline injected mice, but IL-1β returned to normal levels at
the 4 week time point. Saline injected mice showed no difference in mRNA expression of TNF-α, IL-1β, MIF, and IL-6
on the ocular surface tissue at all time points. Immunohistochemistry confirmed these findings.
Conclusions: BTX-B induced mouse model showed decreased aqueous tear production, increased corneal fluorescein
staining, and TNF-α and IL-1β increased expression on the ocular surface within one month. The patterns seen appeared
to mimic those in humans with non-Sjögren’s syndrome keratoconjunctivitis sicca (NS-KCS).
As defined by the International Dry Eye Worskhop, dry
eye is a multifactorial disease of the tears and ocular surface
that results in symptoms of discomfort, visual disturbance,
and tear film instability with potential damage to the ocular
surface. It is accompanied by increased osmolarity of the tear
film and inflammation of the ocular surface [1]. There is a
growing recognition that inflammation plays an important
role  in  dry  eye  syndrome,  which  is  considered  an  ocular
surface inflammatory disease rather than simply a tear film
insufficiency  [2].  Increasing  levels  of  proinflammatory
cytokines and markers have been observed in both the tear
film and ocular surface epithelia of patients with dry eye.
Conjunctival  biopsy  specimens  from  patients  with  both
Sjögren’s syndrome keratoconjunctivitis sicca (SS-KCS) and
non-Sjögren’s  syndrome  keratoconjunctivitis  sicca  (NS-
KCS)  display  lymphocytic  infiltration  and  increased
immunoreactivity for various markers of inflammation and
immune activation, including human leukocyte antigen-DR
(HLA-DR),  HLA-DQ,  intracellular  adhesion  molecule  1
(ICAM-1), CD40, CD40 ligand and apoptotic marker APO2.7
[3,4]. Proinflammatory cytokines interleukin-1α (IL-1α), and
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interleukin-1β  (IL-1β)  have  been  detected  in  human
conjunctival epithelium and tear film in dry eye [5]. Clinical
trials  have  shown  decreased  numbers  of  conjunctival  T
lymphocytes,  HLA-DR,  apoptosis  markers,  and  some
proinflammatory  cytokines  such  as  interleukin  6  in
cyclosporine treated dry eye, accompanied by increased tear
production and decreased corneal fluorescein staining [6-8].
Increased  levels  of  cytokines  have  also  been  observed  in
ocular surface epithelia in dry eye animal models [9-11]. In
an  experimental  tear-deficiency  dry  eye  mouse  model
mimicking  human  non-Sjögren’s  syndrome
keratoconjunctivitis sicca study, IL-1β, tumor necrosis factor-
α (TNF-α), and matrix metalloproteinase-9 (MMP-9) were
significantly  upregulated  in  the  corneal  and  conjunctival
epithelia  [9,10],  and  both  corticosteroid  and  doxycycline
suppressed the expression of MMP-9, IL-1β, IL-1α, and TNF-
α [11].
We have previously developed a mouse tear-deficiency
dry  eye  model  without  lacrimal  gland  inflammation  by
injection of Botulium toxin B (BTX-B) into the lacrimal gland
[12]. BTX-B injected mice displayed significantly decreased
tear production and persistent corneal fluorescein staining
with  no  inflammation  of  the  lacrimal  glands.  Further,  a
lacrimal gland inflammatory cytokine gene expression study
showed that macrophage migration inhibitory factor (MIF)
gene expression was elevated in BTX-B injected mice at 2 and
Molecular Vision 2009; 15:250-258 <http://www.molvis.org/molvis/v15/a25>
Received 29 October 2008 | Accepted 22 January 2009 | Published 30 January 2009
© 2009 Molecular Vision
2504 weeks time points. Other cytokines such as TNF-α, IL-12,
and IL-10 showed no significant change [12]. Lacrimal glands
were  normal  structurally  without  inflammatory  cell
infiltration. In this current study, we used the same mouse
model  to  investigate  inflammatory  cytokine  expression
directly on the ocular surface.
METHODS
Animal model: Female CBA/J mice (age 6–8 weeks; Jackson
Laboratories, Bar Harbor, ME) were used in accordance with
the ARVO Statement for the Use of Animal in Ophthalmic
and Vision Research and approved by the Institutional Animal
Care and Use Committee of Johns Hopkins University.
Mice were divided into three experimental groups, each
group containing eight mice (three for immunohistological
analysis and five for cytokine expression analysis). One group
was used as a control without any injection into lacrimal
glands. The second group of mice was injected with saline into
their lacrimal glands and the third group of mice was injected
with  Botulium  toxin  B  (BTX-B;  Myobloc™;  Elan
Pharmaceuticals  Inc.,  South  San  Francisco,  CA)  into  the
lacrimal glands. The mouse model was created in accordance
with our previously reported method [13]. In brief, all mice in
the second and third groups were anesthetized with Ketamine
and Xylazine (45 mg/kg and 4.5 mg/kg, respectively). Saline
(0.05 ml) or BTX-B (0.05 ml, 20 mU) was injected into the
right lacrimal gland unilaterally through the conjunctiva with
custom made 33 gauge needles (Hamilton, Reno, NV) under
an operating microscope. All mice were maintained under
relatively constant temperature (21 °C to 24 °C) and humidity
conditions (<20%). For the quantitative real-time RT–PCR
and immunohistochemistry study, the animals were sacrificed
at four time points: before BTX-B injection and at 1, 2, and 4
weeks after injection.
Measurement  of  aqueous  tear  production  and  corneal
fluorescein  staining:  Measurements  of  aqueous  tear
production and corneal fluorescein staining were performed
as previously reported [13]. In brief, phenol red-impregnated
cotton  threads  (Zone-Quick;  Oasis,  Glendora,  CA)  were
applied to the ocular surface in the lateral canthus for 15 s in
the  unanesthetized  mouse,  and  then  the  wet  threads  were
measured in millimeters.
Corneal  fluorescein  staining  (1  µl  of  1%  sodium
fluorescein, Sigma-Aldrich, St. Louis, MO) was evaluated
under cobalt blue light with a grading system based on area
of corneal staining as previously reported [13]. The total area
of punctate staining was designated as grade 0 when there was
no punctate staining, grade 1 when equal to or less than one
eighth was stained, grade 2 when equal to or less than one
fourth was stained, grade 3 when equal to or less than one half
was stained, and grade 4 when greater than one half or the
entire  area  was  stained  [14].  All  measurements  were
performed before injection and at 1, 2, and 4 weeks after
injection.
Quantitative Real-Time RT–PCR: Mouse corneal epithelial
cells were obtained by scraping and conjunctival epithelial
cells were obtained by dissection. Care was taken to dissect
the conjunctiva from subconjunctival tissue. Total RNA was
isolated  from  the  ocular  surface  using  the  RNeasy  Kit
(Qiagen,  Valencia,  CA)  according  to  the  manufacturer’s
instructions. Combining the ocular surface epithelia allowed
us to collect sufficient RNA for analysis from each of the 5
animals at each time point. Furthermore, we chose to combine
the ocular surface epithelia because an abnormal tear film
affects both the corneal and conjunctival surfaces. There were
five samples in every group. The concentrations of RNA were
determined by UV spectrophotometry. RNA samples were
treated with DNase I to exclude genomic DNA contamination.
The first-strand cDNA was synthesized from 1 µg of total
RNA with oligo d’-T primer using a commercially available
kit  (SuperScriptTM  Ш  Reverse  Transcriptase;  Invitrogen,
Carlsbad, CA). Samples of cDNA were aliquoted and stored
at –80 °C until use.
Real time quantitative PCR was performed and analyzed
using  the  Roche  Light-Cycler  (Roche  Diagnostics
Corporation, Indianapolis, IN). Reactions in a 20 µl volume
using the SYBR green reaction mix (QIAGEN, Valencia, CA)
with 0.5 mmol/l primer. Cyclophilin A was used as a standard
for normalization. To quantify the gene copy number, an
absolute quantification method was used (Roche). Briefly,
PCR  was  performed  using  PFU-Taq  (Stratagene,  Cedar
Creek,  TX).  PCR  products  were  purified  and  DNA
concentrations  measured  by  spectrophotometry.  Standard
curves  for  each  gene  were  plotted  with  quantified  cDNA
templates during each real-time PCR. Assays were performed
in duplicate. The sequences of the PCR primer pairs are listed
in Table 1.
TABLE 1. PRIMER SEQUENCES FOR REAL-TIME RT PCR.
Gene
GeneBank
accession Left primer Right primer
PCR
Product
(bp)
IL-1β NM_008361 GCCCATCCTCTGTGACTCAT AGGCCACAGGTATTTTGTCG 229
TNF-α NM_013693 GAACTGGCAGAAGAGGCACT AGGGTCTGGGCCATAGAACT 201
MIF NM_010798 GTGCCAGAGGGGTTTCTGT AGGCCACACAGCAGCTTACT 205
IL-6 NM_031168 AGTTGCCTTCTTGGGACTGA CAGAATTGCCATTGCACAAC 190
Cyclophilin A XR_004644 CAGACGCCACTGTCGCTTT TGTCTTTGGAACTTTGTCGCAA 132
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251Immunohistochemistry: For immunofluorescent staining, the
cornea and conjunctiva from each group at different time
points were harvested by dissection and immersed in 4%
paraformaldehyde, fixed overnight at 4 °C, then embedded
and  frozen  in  optimal  cutting  temperature  embedding
compound  (OCT;  Tissue-Tek®;  Sakura,  Terrence,  CA).
Blocks were cryo-sectioned at 10 μm thickness. After drying
at room temperature for 15 min, slides were washed twice with
phosphate buffered saline (PBS) and incubated with blocking
serum for 30 min, then incubated with primary antibodies
overnight at 4 °C. The antibodies used were as follows: anti-
TNF-α  (goat  polyclonal  IgG;  1:200;  Santa  Cruz
Biotechnology,  Inc.,  Santa  Cruz,  CA),  anti-IL-1β  (rabbit
polyclonal IgG; 1:400; Santa Cruz Biotechnology, Inc.), and
anti-MIF  (rabbit  polyclonal  IgG;  1:100;  Santa  Cruz
Biotechnology, Inc.). Slides were washed with PBS, then
secondary  antibodies  conjugated  with  either  Cy3  or  Cy2
Figure 1. Effect of BTX-B on murine tear production. Mean tear
production  in  all  groups.  Data  represents  the  mean±SEM  in  all
groups. x-axis: time after injection. The reduction of aqueous tear
production in BTX-B injected mice persisted during the observation
period, but no change in normal and saline-injected control mice.
Figure 2. Effect of BTX-B on murine corneal staining. Corneal
fluorescein staining scores. Data represents the mean±SEM in all
groups. Average score in BTX-B injected mice was significantly
increased compared with control and saline-injected mice at all time
points (p<0.01). X–axis: time after injection.
(1:100; Jackson Immuno Research, West Grove, PA) were
applied and incubated for 1 h at room temperature. After
washing with PBS, slides were counterstained with Hoechst
33342  nuclear  staining  dye  (1:4,000;  Molecular  Probes,
Eugene, OR) for 30 s and mounted with Mounting Media
(Dako,  Carpinteria,  CA).  Sections  were  visualized  with  a
fluorescence  digital  microscope  (Eclipse;  E1000;Nikon,
Tokyo, Japan). Negative control experiments were performed
by omitting the primary antibody and incubating in antibody
diluent  and  secondary  antibody.  Isotype  controls  were
performed by using normal rabbit IgG (1:400) or normal goat
IgG (1:100; Santa Cruz Biotechnology, Inc.).
Statistical analysis: Statistical analyses were performed using
SPSS for Windows version 10.0 and the two way t-test. Two-
way ANOVA was used for the multiple comparisons between
different  time  points.  P  values  of  less  than  0.05  were
considered statistically significant.
RESULTS
Aqueous  tear  production  and  corneal  staining:  All  mice
retained full blink function after BTX-B injection. BTX-B
injected mice showed significantly decreased aqueous tear
production at the 1 week (1.77±0.72 mm [mean±SD]) and 2
week (1.89±0.74 mm) time points compared with normal
control (2.84±0.88 mm) and saline-injected mice (1 week;
3.13±1.28 mm and 2 weeks; 3.04±1.19 mm post-injection;
p<0.01). The reduction of aqueous tear production persisted
during the majority of the observation period. Aqueous tear
production  tended  to  increase  at  the  4  week  time  point
(2.45±0.52  mm),  but  was  not  statistically  significant
compared  with  normal  control  and  saline-injected  mice
(p=0.097; Figure 1).
Little or no corneal staining in saline-injected and normal
mice was observed at the various time points after injection.
In comparison, BTX-B injected mice showed significantly
greater amounts of corneal fluorescein staining throughout the
observation period (p<0.01; Figure 2 and Figure 3).
Inflammatory cytokine expression on the ocular surface: We
chose  to  evaluate  mRNA  expression  of  the  corneal  and
conjunctival  epithelial  cells  of  the  ocular  surface.  In
accordance  with  our  previous  results  [12],  the  pro-
inflammatory cytokines MIF, IL-1β, TNF-α, and IL-6 were
chosen to evaluate mRNA expression on the ocular surface by
quantitative real-time RT PCR at 1, 2, and 4 weeks post-
operatively using the housekeeping gene cyclophilin A as the
internal control. The BTX-B injected mice mRNA expression
levels of TNF-α and IL-1β increased significantly at two early
time points comparing with that of normal (0 week) and saline
injected mice, but IL-1β returned to normal levels at the 4
week time point (p=0.417). Saline injected mice showed no
difference in mRNA expression of TNF-α, IL-1β, MIF, and
IL-6 on the ocular surface tissue at all time points (Figure 4).
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252Immunohistochemistry:  Figures  5,  Figure  6,  and  Figure  7
show typical immunolabeling of normal and saline- injected
mouse cornea and conjunctiva with anti-TNF-α, IL-1β, and
MIF antibodies. Very weak staining located in corneal and
conjunctival epithelia was detected for TNF-α (Figure 5) and
IL-1β (Figure 6), while MIF was expressed constitutively
(Figure 7) in normal corneas. The corneal (basal, suprabasal,
and apical epithelia) and conjunctival epithelia of BTX-B
injected mice demonstrated strong staining for TNF-α (Figure
5C-D,H-I,M-N,R-S) and IL-1β (Figure 6C-D,H-I,M-N,R-S)
at  the  1  and  2  week-time  points,  whereas  the  staining
decreased at the 4 week time point. MIF expression displayed
no change in BTX-B injected mice compared with normal and
saline-injected mice.
DISCUSSION
In  this  study,  we  found  increased  expression  of  the  pro-
inflammatory cytokines IL-1β and TNF-α in the corneal and
conjunctival epithelium of BTX-B lacrimal gland-injected
Figure 3. Corneal fluorescein staining in
BTX-B  injected  and  normal  control
mice. A-C: Corneal staining was seen in
BTX-B injected mice 1 week, 2 weeks,
and  4  weeks  post-injection,
respectively.  D-F:  No  corneal
fluorescein staining was noted in normal
control  mice,  saline-injected  mice  1
week  and  2  weeks  post-injection,
respectively.
Figure 4. Inflammatory cytokine mRNA
expression in ocular surface epithelia of
BTX-B  injected  and  normal  control
mice. mRNA expression levels of TNF-
α  and  IL-1β  in  BTX-B  injected  mice
increased  significantly  at  early  time
points, but normal and saline-injected
control  mice  showed  no  significant
difference.  Total  RNAs  were  isolated
from cornea and conjunctiva at different
time points after BTX-B injection and
uninjected contra-lateral eyes were used
as controls. Each time point contained
five samples. Results are represented as
the ratio of cytokine copy number and
Cyclophilin  A.  Error  bar:  standard
deviation  of  each  group.  Black  bar:
BTX-B  injected  groups,  empty  bar:
Saline-injected  groups.  The  asterisk
indicates  significant  differences
between the two groups (p<0.01). The
rest  without  asterisks  denote  no
significant differences between the two
groups (p>0.05).
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253Figure 5. Immunofluorescent staining with TNF-α specific antibody in corneal and conjunctival epithelia. Immunofluorescence staining with
TNF- α specific antibody (green) in corneal epithelia (CE: arrows) and conjunctival epithelia (CJE: arrow heads) at all time points. The staining
for TNF-α localized in CE and CJE was strong in BTX-B injected mice. Nuclear staining (blue). (F-J) and (P-T): merged pictures. Images
of isotype and negative control were omitted with no staining. Scale bar: 50 μm.
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254Figure 6. Immunofluorescent staining with IL-1β specific antibody in corneal and conjunctival epithelia. Immunofluorescence staining with
IL-1β specific antibody (red) in corneal epithelia (CE: arrows) and conjunctival epithelia (CJE: arrow heads) at all time points. The staining
for IL-1β localized in CE and CJE was strong in BTX-B injected mice. Nuclear staining in blue. (F-J) and (P-T) merged pictures. Images of
isotype and negative control were omitted with no staining. Scale bar: 50 μm.
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255Figure 7. Immunofluorescent staining of MIF in corneal and conjunctival epithelia. Immunofluorescence staining demonstrated the presence
of MIF (red) in corneal epithelia (CE: arrows) and conjunctival epithelia (CJE: arrow heads) at all time points. The staining was detected in
normal (A, E, I, and M) and BTX-B injected mice (B, F, J, and N) and saline-injected mice (D, H, L, and P) and showed no difference (C,
G, K, and O). Negative control with no staining. Isotype control was omitted with no staining. Scale bar: 50 μm.
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256mice over 4 weeks, coincident with observed tear production
decrease and corneal fluorescein staining increase.
We  have  confirmed  that  ocular  surface  inflammation
develops  in  the  BTX-B  induced  dry  eye  mouse  model.
Comparing normal and saline-injected mice, IL-1β and TNF-
α mRNA expression in the corneal and conjunctival epithelia
significantly increased in BTX-B injected mice at 1 and 2
weeks after injection, and decreased back toward baseline at
4  weeks,  especially  IL-1β.  Immunohistological  staining
results support the findings of the gene expression study.
These changes were also consistent with observed alterations
in tear production.
In a previous study, we found that IL-1β and TNF-α
expression in the lacrimal gland did not increase, but they were
increased  in  corneal  and  conjunctival  epithelia  in  BTX-B
injected mice in the present study. The role of these cytokine
increases remains unclear. One possible explanation for the
disparity in inflammatory cytokine expression between the
lacrimal gland and the ocular surface is that BTX-B imparts
a pure aqueous deficiency, and the inflammatory changes on
the ocular surface are secondary reactive changes. Previous
work  supports  this  hypothesis  in  that  secondary  tear
hyperosmolarity and micro-abrasive effects of blinking may
lead to upregulation of cytokines such as TNF-α and IL-1 in
the ocular surface. Further studies propose that one of the
original stimuli may come from the tear deficiency-related
hyperosmotic stress on the ocular surface, which activates
stress JNK, ERK, or P38 MAPK signaling pathways, and the
activated  MAPK  signaling  pathway  plays  a  role  in  the
induction of inflammatory cytokines IL-1β and TNF-α [9,
15].
An  interesting  finding  in  this  study  is  that  MIF  was
expressed constitutively in corneal and conjunctival epithelia
of our mice, and that there was no significant change in the
BTX-B-induced dry eye mouse model. In our previous study,
we found that MIF was elevated in the lacrimal gland and tear
fluid at 2 weeks after BTX-B injection [12]. MIF is a potent
activator  of  T-lymphocytes  in  some  other  inflammatory
diseases  [16,17],  but  the  function  of  MIF  in  the  lacrimal
functional unit is remains unclear. However, it has recently
been  demonstrated  that  MIF,  abundantly  expressed  in
neovascularized mouse corneas, has an angiogenic role in
inflammatory  corneal  neovascularization.  Furthermore,
homozygous MIF-deficient mice displayed significantly less
corneal  neovascularization  and  stromal  inflammatory  cell
infiltration [18]. Further studies are underway incorporating
both overexpressing MIF transgenic as well as MIF knockout
mice in hopes of better understanding the role of this potent
inflammatory mediator in our dry eye mouse model.
In  conclusion,  we  have  demonstrated  the  increased
expression of the pro-inflammatory cytokines IL-1β and TNF-
α in the corneal and conjunctival epithelium of lacrimal gland
in BTX-B-injected mice over 4 weeks, as well as decreased
tear production and increased corneal fluorescein staining.
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